Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

03-12-2018 | Uitgave 3/2019

Quality of Life Research 3/2019

Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery

Tijdschrift:
Quality of Life Research > Uitgave 3/2019
Auteurs:
C. Quinten, C. Kenis, L. Decoster, P. R. Debruyne, I. De Groof, C. Focan, F. Cornelis, V. Verschaeve, C. Bachmann, D. Bron, S. Luce, G. Debugne, H. Van den Bulck, J. C. Goeminne, A. Baitar, K. Geboers, B. Petit, C. Langenaeken, R. Van Rijswijk, P. Specenier, G. Jerusalem, J. P. Praet, K. Vandenborre, M. Lycke, J. Flamaing, K. Milisen, J. P. Lobelle, H. Wildiers
Belangrijke opmerkingen

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s11136-018-2062-6) contains supplementary material, which is available to authorized users.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Purpose

Using the EORTC Global Health Status (GHS) scale, we aimed to determine minimal clinically important differences (MCID) in health-related quality of life (HRQOL) changes for older cancer patients with a geriatric risk profile, as defined by the geriatric 8 (G8) health screening tool, undergoing treatment. Simultaneously, we assessed baseline patient characteristics prognostic for HRQOL changes.

Methods

Our analysis included 1424 (G8 ≤ 14) older patients with cancer scheduled to receive chemotherapy (n = 683) or surgery (n = 741). Anchor-based methods, linking the GHS score to clinical indicators, were used to determine MCID between baseline and follow-up at 3 months. A threshold of 0.2 standard deviation (SD) was used to exclude MCID estimates too small for interpretation. Logistic regressions analysed baseline patient characteristics prognostic for HRQOL changes.

Results

The 15-item Geriatric Depression Scale (GDS15), Visual Analogue Scale (VAS) for Fatigue and ECOG Performance Status (PS) were selected as clinical anchors. In the surgery group, MCID estimates for improvement and deterioration were ECOG PS (5*, 11*), GDS15 (5*, 2) and VAS Fatigue (3, 9*). In the chemotherapy group, MCID estimates for improvement and deterioration were ECOG PS (8*, 7*), GDS15 (5, 4) and VAS Fatigue (5, 5*). Estimates with * were > 0.2 SD threshold. Patients experiencing pain or malnutrition (surgery group) or fatigue (chemotherapy group) at baseline showed a significantly stable or improved HRQOL (p < 0.05) after their treatment.

Conclusion

The reported MCID for improvement and deterioration depended on the anchor used and treatment received. The estimates can be used to evaluate significant changes in HRQOL and to determine sample sizes in clinical trials.

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Extra materiaal
Supplementary material 1 (DOCX 17 KB)
11136_2018_2062_MOESM1_ESM.docx
Literatuur
Over dit artikel

Andere artikelen Uitgave 3/2019

Quality of Life Research 3/2019 Naar de uitgave